In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

The importance of a successful cardiac rehabilitation program - long-term prognosis of cardiac patients following rehabilitation

Session Young Investigator Award 3 - Secondary prevention and rehabilitation Section

Speaker Nicolai Mikkelsen

Event : ESC Preventive Cardiology (Formerly EuroPrevent) 2019

  • Topic : preventive cardiology
  • Sub-topic : Cardiovascular Rehabilitation
  • Session type : Young Investigator Award Abstracts

Authors : N Mikkelsen (Copenhagen,DK), C Cadarso-Suarez (Santiago de Compostela,ES), O Lado-Baleato (Santiago de Compostela,ES), C Diaz-Louzao (Santiago de Compostela,ES), J Reeh (Copenhagen,DK), H Rasmusen (Copenhagen,DK), E Prescott (Copenhagen,DK)

Authors:
N Mikkelsen1 , C Cadarso-Suarez2 , O Lado-Baleato2 , C Diaz-Louzao2 , J Reeh1 , H Rasmusen1 , E Prescott1 , 1Bispebjerg University Hospital, Department of Cardiology - Copenhagen - Denmark , 2University of Santiago de Compostela, Unit of Biostatistics, Department of Statistics - Santiago de Compostela - Spain ,

Citation:

Introduction

It is well documented that participants in CR have a better long-term prognosis than non-participants. However, differences in long-term prognosis might also be present within the patients that complete CR. We investigated whether change in VO2peak following CR was a predictor for long-term prognosis in terms of future cardiovascular events and all-cause mortality.

Methods

This was a retrospective study on cardiac patients who completed a CR program at a CR unit in Copenhagen from 2011-2017. Effect of CR was defined as change in VO2peak (assessed before and after CR) and outcomes were defined as subsequently suffering a new cardiovascular event (recurrent MI, unstable angina, heart failure or stroke) and/or death. We used a multi-state model with three transitions to predict new cardiovascular events and all-cause mortality (see figure 1). All patients were at risk of having a new cardiovascular event (transition 1). If suffering a new cardiovascular event, they were subsequently at risk of dying (transition 2). The patients that did not suffer a new cardiovascular event were similarly at risk of dying (transition 3).

Results

1237 patients completed CR and had full data on VO2peak and explanatory variables. Mean follow-up time was 2.5 years. Approximately 30 percent of the patients did not improve in VO2peak following rehabilitation.

156 patients suffered a cardiovascular event (transition 1). Improvement in VO2peak associated with a decreased risk of a future cardiovascular event, even after adjustment for age, gender, index diagnoses, comorbidities and baseline VO2peak, see figure 2. 25 patients died after suffering a new cardiovascular event (transition 2) and this was not associated change in VO2peak. 50 patients died without suffering a new event (transition 3) and this risk was highly associated with change in VO2peak with a linear decrease of 21.12 % of risk of death for each unit of VO2peak improvement, also after full adjustment.

Conclusion

Change in VO2peak after CR is a highly relevant parameter in prediction of future cardiovascular events and of all-cause mortality.

The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are